Cancer Risk Estimates: What Do Those Numbers Mean?
Epidemiologist Elizabeth A. Platz explains what goes into calculating cancer risk estimates, such as rate ratio, hazard ratio, and absolute risk.
Progress Against Cancer
Epidemiologist Elizabeth A. Platz explains what goes into calculating cancer risk estimates, such as rate ratio, hazard ratio, and absolute risk.
Zongertinib was granted accelerated approval as a first-line treatment for adults with advanced non-squamous non-small cell lung cancer with HER2-activating mutations. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zongertinib...
The FDA has converted the accelerated approval of encorafenib and cetuximab plus chemotherapy to full approval for first-line treatment of certain colorectal cancers. The U.S. Food and Drug Administration (FDA) has granted traditional approval...
First tumor treating fields device for pancreatic cancer approved, and hair extension products often contain potentially dangerous chemicals.
Elizabeth M. Jaffee and Philip D. Greenberg opened AACR IO 2026 with a look at cancer vaccines and the next generation of engineered T cells.
The second-generation BTK inhibitor acalabrutinib was approved for use with venetoclax. The U.S. Food and Drug Administration (FDA) approved acalabrutinib (Calquence) in combination with venetoclax (Venclexta) for adults with chronic lymphocytic leukemia (CLL) or...
Colorectal cancer cases are becoming more common in younger adults, but there are now more options for screening beyond colonoscopies.
Misinformation reaches most breast cancer survivors, and the FDA approves a treatment combination for platinum-resistant epithelial ovarian cancer.
The FDA has approved the portable device Optune Pax for non-invasive at-home treatment of locally advanced pancreatic cancer. The U.S. Food and Drug Administration (FDA) approved Optune Pax, a portable, noninvasive device for the...
Researchers and a patient advocate weighed in on current and emerging treatment options for each stage of triple-negative breast cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More